Skip to content Skip to footer
Viewpoints_Martin Kilsgård

Martin Kilsgård, Head of Product at Trialbee, Shares Insights from the Launch of Trialbee Honey™ Analytics at DPHARM 2022

Shots: Martin gave a detailed view of the newly launched Honey Analytics module associated with the Trialbee Honey™ platform He also talked about the how Trialbee Honey platform will help in the screening and recruiting of patients specifically in remote areas The interview gives a profound understanding of how Trialbee is developing real-time monitoring modules…

Read more

Viewpoints_Natalie Shiff

Natalie Shiff, Associate Medical Director, Janssen Rheumatology Shares Insights from the FDA Approval of Stelara to Treat Pediatric Patients with Active Psoriatic Arthritis

Shots: Natalie spoke about the study design and key findings from the P-III study evaluating Stelara for the treatment of pediatric patients with active psoriatic arthritis She also spoke about the patient support program that is executed by Janssen to support patients to get Stelara  The interview gives an understanding of how Janssen is advancing…

Read more

Insights+ EMA Marketing Authorization of New Drugs in September 2022

Insights+: EMA Marketing Authorization of New Drugs in September 2022

The EMA approved 7 New Chemical Entity (NCE) and 4 Biologic Drugs in Sept 2022, leading to treatments for patients and advances in the healthcare industry In September 2022, the major highlights drugs were Imcivree approval for bardet-biedl syndrome, Opdualag for unresectable or metastatic melanoma, Ultomiris for generalised myasthenia gravis PharmaShots has compiled a list…

Read more

Viewpoints_Garret Hampton

Garret Hampton, President, Clinical Sequencing & Oncology at Thermo Fisher Scientific Shares Insights from the Approval of the First NGS-Based Companion Diagnostic for HER2-Mutant NSCLC

Shots: Garret spoke about the approval of the first NGS-based companion diagnostic to aid in selecting NSCLC patients with HER2  activating mutations for treatment with ENHERTU Garret also talked about the Oncomine Dx Target Test and its availability for different targeted therapies in multiple geographies The interview highlights how Thermo Fisher is working to develop accessible CDx solutions…

Read more

Viewpoints_Josh Rubel

Josh Rubel, CCO at MDClone, Shares Insights on the Partnership with MCI Onehealth to Accelerate Research through Global Clinical Intelligence Offering

Shots: Josh spoke about the collaboration with MCI Onehealth. The collaboration will provide access to high-value data insights as a service for an array of research, clinical, and data science needs Josh also talked about MDClone’s ADAMS platform which has a unique ability to convert datasets and cohorts of interest into synthetic files that are…

Read more

Disease of the Month: Cerebral Palsy

Disease of the Month: Cerebral Palsy

INTRODUCTION Cerebral Palsy is a group of neurological disorders which affect motor and developmental skills. It causes disability in muscle tone, movement, balance, and posture. It is the most common motor disability in childhood with an estimated prevalence ranging from 1-4 per 1,000 live births. The incidence of CP is more in preterm or low…

Read more